* previous hypersensitivity or allergic reactions to clazakizumab * lactating or pregnant females * subjects with latent tuberculosis (tb) and who are not receiving treatment * subjects with active tb * a significantly abnormal general serum screening lab result defined as a white blood count (wbc) \< 3.0 x 103/ml, a hgb \< 8.0 g/dl, a platelet count \< 50 x 103/ml, a serum glutamic oxaloacetic transaminase (sgot) or serum glutamic pyruvic transaminase (sgpt) \> 5x upper limit normal * participation in another clinical trial investigating covid-19 aimed agents

* previous hypersensitivity or allergic reactions to clazakizumab * lactating or pregnant females * subjects with latent tuberculosis (tb) and who are not receiving treatment * subjects with active tb * a significantly abnormal general serum screening lab result defined as a white blood count (wbc) \< 3.0 x 103/ml, a hgb \< 8.0 g/dl, a platelet count \< 50 x 103/ml, a serum glutamic oxaloacetic transaminase (sgot) or serum glutamic pyruvic transaminase (sgpt) \> 5x upper limit normal * participation in another clinical trial investigating covid-19 aimed agents

previous hypersensitivity or allergic reactions to clazakizumab lactating or pregnant females subjects with latent tuberculosis (tb) and who are not receiving treatment subjects with active tb a significantly abnormal general serum screening lab result defined as a white blood count (wbc) < 3.0 x 103/ml, a hgb < 8.0 g/dl, a platelet count < 50 x 103/ml, a serum glutamic oxaloacetic transaminase (sgot) or serum glutamic pyruvic transaminase (sgpt) > 5x upper limit normal participation in another clinical trial investigating covid-19 aimed agents

previous hypersensitivity or allergic reactions to clazakizumab lactating or pregnant females subjects with latent tuberculosis (tb) and who are not receiving treatment subjects with active tb a significantly abnormal general serum screening lab result defined as a white blood count (wbc) < 3.0 x 103/ml, a hgb < 8.0 g/dl, a platelet count < 50 x 103/ml, a serum glutamic oxaloacetic transaminase (sgot) or serum glutamic pyruvic transaminase (sgpt) > 5x upper limit normal participation in another clinical trial investigating covid-19 aimed agents

- previous hypersensitivity or allergic reactions to clazakizumab - lactating or pregnant females. - subjects with latent tb and who are not receiving treatment. - subjects with active tb - a significantly abnormal general serum screening lab result defined as a wbc < 3.0 x 103/ml, a hgb < 8.0 g/dl, a platelet count < 50 x 103/ml, an sgot or sgpt > 5x upper limit normal - participation in another clinical trial investigating covid-19 aimed agents

- previous hypersensitivity or allergic reactions to clazakizumab - lactating or pregnant females. - subjects with latent tb and who are not receiving treatment. - subjects with active tb - a significantly abnormal general serum screening lab result defined as a wbc < 3.0 x 103/ml, a hgb < 8.0 g/dl, a platelet count < 50 x 103/ml, an sgot or sgpt > 5x upper limit normal - participation in another clinical trial investigating covid-19 aimed agents